Neuropathy

94

Pipeline Programs↗

21

Active Trials↗

57

Companies Involved↗

Neuropathy is a moderately active landscape with 94 programs across 57 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, United BioPharma, Jazz Pharmaceuticals. 13 therapies are approved with 18 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

25/100

Mech. Concentration

11/100

Completion Rate

74/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

United BioPharma

1 program

Jazz Pharmaceuticals

1 program

Seelos Therapeutics, Inc.

1 program

Auson Pharmaceuticals Inc.

1 program

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

2 programs

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

99 of 106 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 106 classified programs, each share of the total. Modality classified for 98% of 115 pipeline programs.

Analysis

Trial Status

116

clinical trials

Completed58 · 50%

Unknown status15 · 13%

Terminated13 · 11%

Recruiting13 · 11%

Withdrawn6 · 5%

Not yet recruiting4 · 3%

Other7 · 6%

Clinical Trials

Trial Activity

116 trials

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

Recruiting·—·Phase 2·NCT06906081·100 enrolled

Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy

Recruiting·WWuhan Neurophth Biotechnology Limited Company·Phase 2/3·NCT04912843·102 enrolled

Chemotherapy Induced Neuropathy in Cancer Patients

Recruiting·SSwami Rama Himalayan University·N/A·NCT06491082·124 enrolled

Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy

Recruiting·VVirginia Commonwealth University·Phase 2·NCT05259527·120 enrolled

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Recruiting·UUniversity of California, Davis·Phase 2·NCT06268665·86 enrolled

Comparison of the Efficacy and Safety of Duloxetine Augmented With Gabapentin and Duloxetine Augmented With Amitriptyline vs Duloxetine Alone in Chemotherapy -Induced Neuropathy

Recruiting·—·Phase 2·NCT06091553·160 enrolled

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

Recruiting· Argenx logo

Argenx·Phase 3·NCT06742190·115 enrolled

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Recruiting·EEndeavor Health·Phase 2·NCT04153422·20 enrolled

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Recruiting·FFox Chase Cancer Center·Phase 1·NCT07167446·30 enrolled

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Recruiting·EEmory University·Phase 2·NCT06492070·70 enrolled

The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT06461377·50 enrolled

Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).

Recruiting·—·Phase 2/3·NCT06799351·42 enrolled

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)

Recruiting·DDianthus Therapeutics·Phase 2·NCT06537999·36 enrolled

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Active, not recruiting· Argenx logo

Argenx·Phase 2·NCT05405361·51 enrolled

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Active, not recruiting·—·Phase 2·NCT05065554·12 enrolled

Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)